SequelSEC

GeneDx Holdings Corp. WGS

Services-Health Services · CIK 0001818331 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$114.44M
Fiscal year ended 2026-06-30
Operating income
-$17.46M
Fiscal year ended 2026-06-30
Free cash flow
-$39.10M
Fiscal year ended 2026-06-30

GeneDx Holdings Corp. (WGS) reported revenue of $114.44M and net income of -$17.74M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from GeneDx Holdings Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Health Services.

Income

GeneDx Holdings Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$114.44M$102.25M$120.99M$116.74M$102.69M$87.12M$95.64M$76.87M$70.51M$62.42M
Cost of revenue$36.20M$34.04M$36.72M$32.22M$31.79M$28.64M$29.44M$29.04M$27.56M$25.01M
Gross profit$78.24M$68.21M$84.27M$84.53M$70.90M$58.48M$66.20M$47.83M$42.95M$37.41M
Operating income-$17.46M-$57.47M-$14.24M-$3.25M$8.96M-$4.55M$8.81M-$7.78M-$10.58M-$13.66M
Net income-$17.74M-$63.32M-$17.67M-$7.64M$10.81M-$6.53M$5.44M-$8.31M-$29.17M-$20.24M
Research & development$19.66M$19.80M$24.54M$19.83M$15.08M$12.58M$11.59M$11.66M$10.90M$11.57M
Weighted-average diluted sharesshares 29.71Mshares 29.34MUnavailableshares 28.80Mshares 29.75Mshares 28.15MUnavailableshares 27.10Mshares 26.62Mshares 26.06M
Pretax income-$18.26M-$62.42M-$18.23M-$7.39M$10.56M-$6.08M$5.41M-$8.36M-$29.36M-$20.32M
Income tax expense-$518.00K$897.00K-$564.00K$247.00K-$246.00K$447.00K-$24.00K-$47.00K-$190.00K-$82.00K
Diluted EPS$-0.60$-2.16Unavailable$-0.27$0.36$-0.23Unavailable$-0.31$-1.10$-0.78
Selling, general & administrative$76.04M$74.59M$73.96M$67.95M$46.86M$50.45M$45.81M$43.94M$42.63M$39.50M
General & administrativeUnavailableUnavailable$46.83M$44.44M$27.42M$32.13M$28.14M$26.92M$26.04M$23.42M
Selling & marketingUnavailableUnavailable$27.13M$23.51M$19.45M$18.32M$17.68M$17.02M$16.58M$16.08M

Balance

GeneDx Holdings Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$60.32M$93.92M$105.00M$95.97M$74.12M$99.70M$85.21M$57.89M$56.08M$83.67M
Total assets$481.49M$506.30M$523.71M$493.90M$463.86M$446.43M$419.38M$408.84M$389.10M$394.53M
Current assets$246.36M$270.63M$268.29M$237.58M$204.84M$225.82M$197.97M$186.01M$162.17M$163.42M
Total liabilities$237.26M$252.18M$215.53M$201.64M$186.73M$189.02M$174.13M$204.34M$195.06M$187.31M
Current liabilities$74.63M$87.64M$108.91M$87.62M$71.41M$69.54M$54.82M$77.34M$68.27M$50.73M
Total equity incl. NCI$244.22M$254.12M$308.18M$292.26M$277.13M$257.40M$245.25M$204.50M$194.04M$207.22M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$17.82M$12.24M$13.95M$10.57M$11.93M$12.66M$10.65M$10.77M$10.32M$11.62M
Accounts receivable$83.61M$76.93M$74.37M$60.94M$48.03M$45.98M$37.63MUnavailableUnavailableUnavailable
Goodwill$1.64M$1.64M$13.52M$12.80M$12.93MUnavailable$0UnavailableUnavailableUnavailable
Long-term debt$96.84M$96.73M$48.18M$51.58M$51.68M$51.79M$51.91M$52.03M$52.16M$52.29M
Accounts payable$5.15M$11.17M$2.46M$2.63M$3.52M$15.86M$7.95M$9.02M$8.13M$9.48M

Cash flow

GeneDx Holdings Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$28.98M-$32.41M-$3.09M$15.77M$10.42M$10.18M-$3.18M-$4.40M-$4.50M-$16.41M
Capital expenditures$10.11M$6.45M$4.35M$6.17M$2.37M$6.13M$3.05M$646.00K$1.35M$443.00K
Investing cash flow-$5.63M-$17.26M-$11.07M-$4.69M-$36.35M-$9.41M-$519.00K-$7.76M-$22.70M$843.00K
Financing cash flow$1.00M$38.59M$23.19M$10.77M$346.00K$13.72M$31.02M$13.97M-$391.00K-$438.00K
Net change in cash-$33.61M-$11.07M$9.03M$21.85M-$25.58M$14.49M$27.32M$1.82M-$27.60M-$16.01M
Stock-based compensation$6.34M$9.00M$9.78M$10.59M$7.81M$3.98M$2.84M$3.64M$3.11M-$451.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.10M$2.70M$6.88M$2.37M$2.30M$2.20M$2.02M$2.42M$1.71M$1.74M

Derived

GeneDx Holdings Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$39.10M-$38.86M-$7.44M$9.60M$8.05M$4.05M-$6.23M-$5.04M-$5.86M-$16.86M
Gross margin68.4%66.7%69.6%72.4%69.0%67.1%69.2%62.2%60.9%59.9%
Operating margin-15.3%-56.2%-11.8%-2.8%8.7%-5.2%9.2%-10.1%-15.0%-21.9%
FCF margin-34.2%-38.0%-6.1%8.2%7.8%4.7%-6.5%-6.6%-8.3%-27.0%
SBC / revenue5.5%8.8%8.1%9.1%7.6%4.6%3.0%4.7%4.4%-0.7%
Current ratio3.30x3.09x2.46x2.71x2.87x3.25x3.61x2.41x2.38x3.22x
Revenue YoY growth11.4%17.4%26.5%51.9%45.6%39.6%66.6%44.2%44.8%44.7%
Net margin-15.5%-61.9%-14.6%-6.5%10.5%-7.5%5.7%-10.8%-41.4%-32.4%
R&D / revenue17.2%19.4%20.3%17.0%14.7%14.4%12.1%15.2%15.5%18.5%
CapEx / revenue8.8%6.3%3.6%5.3%2.3%7.0%3.2%0.8%1.9%0.7%
Long-term debt / equity0.40xUnavailable0.16x0.18xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable-2.3%Unavailable-0.4%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open WGS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-23View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-29View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.